Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- TLX +2.9%
Other news:
- ORGO +20.1% (successful FDA meeting and plans to file BLA for ReNu; achieves primary endpoint in randomized controlled trial of PuraPlyAM)
- ACIU +10.7% (announces agreement with Eli Lilly to amend collaboration agreement for Morphomer Tau aggregation inhibitor small molecules for the potential treatment of Alzheimer's disease)
- HUM +9.7% (CMS finalizes 2027 Medicare Advantage and Part D payment policies)
- XPOF +7.3% (explores strategic alternatives, including potential sale or merger)
- CVS +7% (CMS finalizes 2027 Medicare Advantage and Part D payment policies)
- UNH +5.9% (CMS finalizes 2027 Medicare Advantage and Part D payment policies)
- ELV +5.7% (CMS finalizes 2027 Medicare Advantage and Part D payment policies)
- SCVL +5.4% (CFO bought 31,000 shares at $16.13 worth ~$500K)
- LZM +5.1% (produces first-ever platinum, palladium and rhodium from its U.S. PGM Recycling ProjectLifezone's Simulus Laboratories completes locked-cycle and pilot test work)
- CLYM +3.9% (receives FDA Fast Track designation for budoprutug in rare kidney disease)
- BNL +3.5% (to join S&P SmallCap 600)
- AVGO +3.3% (enters long-term agreement with Google)
- PTEN +2.5% (reports March 2026 drilling activity)
- GLSI +2% (provides update on patent claims potentially doubling GP2 market potential)
- FENC +1.9% (announced the initiation of an investigator-sponsored study by University of Arizona Cancer Center to evaluate use of PEDMARK)
- BWMX +1.5% (appoints new CFO)